The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy
Article first published online: 27 JAN 2013
© 2012 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Volume 11, Issue 1, pages 124–131, January 2013
How to Cite
ROACH, R. E. J., LIJFERING, W. M., HELMERHORST, F. M., CANNEGIETER, S. C., ROSENDAAL, F. R. and van HYLCKAMA VLIEG, A. (2013), The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. Journal of Thrombosis and Haemostasis, 11: 124–131. doi: 10.1111/jth.12060
- Issue published online: 27 JAN 2013
- Article first published online: 27 JAN 2013
- Accepted manuscript online: 8 NOV 2012 10:31AM EST
- Received 26 June 2012, accepted 31 October 2012
- oral contraception;
- postmenopausal hormone therapy;
- venous thrombosis
Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013; 11: 124–31.
Summary. Background: Oral contraception (OC) and postmenopausal hormone therapy (HT) can be used to alleviate menopausal symptoms. However, the risk of venous thrombosis (VT) associated with OC use in women over 50 years old has never been assessed and the two preparations have not been directly compared. Objectives: To determine and compare the risk of VT associated with OC and HT use. Methods: From a large case–control study, 2550 women aged over 50 years old, 1082 patients with a first VT and 1468 controls, were included. Odds ratios (ORs) and 95% confidence intervals for VT were calculated for OC-users (164 patients and 54 controls) and HT-users (88 patients and 102 controls) compared with non-hormone users (823 patients and 1304 controls). Results: OC-users had a 6.3-fold (4.6–9.8) increased risk of VT. This ranged from 5.4 (3.3–8.9) for preparations containing levonorgestrel to 10.2 (4.8–21.7) for desogestrel. The VT-risk associated with oral HT use was 4.0 (1.8–8.2) for conjugated equine estrogen combined with medroxyprogesterone acetate and 3.9 (1.5–10.7) for micronized estradiol combined with norethisterone acetate. Non-oral HT did not increase the risk of VT: OR 1.1 (0.6–1.8). Relative risk estimates were further increased in hormone users with factor V Leiden, prothrombin G20210A or blood group non-O and hormone users with a family history of VT. Conclusions: In this study, non-oral HT seemed to be the safest hormonal preparation in women over 50 years old. OC use increased the VT risk the most, especially in women with inherited thrombophilia or a family history of VT.